Improving Patient Adherence and Quality of Life in Advanced Renal Cell Carcinoma (RCC): Anticipating and Managing Immune-Related Adverse Events

A continuing medical education activity sponsored by NAMCP and AAMCN.

Novel Treatment Approaches in the Management of Renal Cell Carcinoma (RCC): A Closer Look at Advances in Immunotherapy in an Evolving Treatment Paradigm is a 3-part live webinar series that will provide attendees with the latest information on Renal Cell Carcinoma

This is Part 1 of the series focusing on Improving Patient Adherence and Quality of Life

This activity is an archive from the webinar held July 26, 2019

This activity is valid from September 1, 2019 to October 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

Description:
Managed Care and clinical decision-making in the setting of advanced renal cell carcinoma (RCC) has been undergoing dramatic change in the past few years. The approval of new immunotherapeutic agents has expanded the lines of therapy available to patients, especially around combination options, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in advanced RCC.

Upon completion of this activity, participants will be able to:

  • Discuss challenges to patient adherence and quality of life when utilizing immunotherapy in advanced RCC

  • Explore strategies to monitor and manage adverse events associated with immunotherapies and immunotherapy combination options in advanced RCC in order to improve patient adherence and quality of life

  • Review recent clinical trial data around the safety of immunotherapies in advanced RCC, both alone and in combination, and their effect on patient quality of life

  • Identify patients with advanced RCC who would potentially benefit from, and be able to tolerate, immunotherapies, either alone or in combination
     

Faculty: Brian I. Rini, MD
Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute

Disclosure:

Dr. Rini serves as a consultant for BMS, Pfizer, GNE/Roche, Aveo, Novartis, Synthorx, Peloton, Compugen, Merck, Corvus, and Exelixis. He has in the past received grant or research support from: Pfizer, Merck, GNE/Roche, Peloton, Aveo, Astra-Zeneca and BMS. He owns stock in PTC therapeutics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue